Main symposia
Plenary lectures
Main Symposia
Research group sessions
Special sessions
Sponsored sessions
Corporate symposia
| S1 Clinical diabetes and therapeutics 1 : Youth-onset type 2 diabetes |
09:00~11:00 / Friday 7 October Convention Hall A, 4F Chairman:In-Kyu Lee, Hak Chul Jang |
Overview |
|---|---|---|
| The prevalence of type 2 diabetes in adolescents and young adults is rapidly increasing. Onset of diabetes at earlier lifetime is associated with longer disease exposure and increased risk of chronic complications. In this session, recent findings on youth-onset type 2 diabetes including definition and epidemiology, unique genetic susceptibility to type 2 diabetes in youth, long-term complications, and treatment options and current guidelines of care will be discussed. | ||
|
S1-1Youth-onset type 2 diabetes: definition and natural history in Korea | |
|
S1-2Differences between adult-onset and youth-onset type 2 diabetes – genetic perspectives | |
|
S1-3Treatment options and current guidelines of care | |
|
S1-4Long-term complications in youth-onset type 2 diabetes | |
| S7 Clinical diabetes and therapeutics 2 : Personalized medicine in therapy for type 2 diabetes |
16:00~18:00 / Friday 7 October Convention Hall A, 4F Chairman:Kyoil Suh, Joong Yeol Park |
Overview |
|---|---|---|
| Individualization of therapy, a current health care trend especially in chronic diseases such as diabetes, is based on a hope that personalized approaches would ultimately result in improved outcomes. In type 2 diabetes, the availability of various pharmacological therapies for blood glucose control has significantly increased the complexity involved in managing the condition. This session titled “Personalized medicine in therapy for type 2 diabetes” is a clinical session designed to provide a motive for clinicians and researchers to approach type 2 diabetes in more individual aspects. Four invited speakers will discuss different topics on this perspective. This session is expected to promote an understanding in personalized treatment of type 2 diabetes and incorporate it in real clinical practice. | ||
|
S7-1Current status of antidiabetic agents usage in Korea, and the future? | |
|
S7-2Comparative effectiveness for second-line therapy - GRADE trial | |
|
S7-3TriMaster trial: implications for precision medicine | |
|
S7-4Quadruple oral combination therapy for type 2 diabetes - is it reasonable? | |
| S10 Clinical diabetes and therapeutics 3 : Management of T1DM: guidelines and actual clinical practice |
09:00~11:00 / Saturday 8 October Convention Hall A, 4F Chairman:Kun-Ho Yoon, Byung-Joon Kim |
Overview |
|---|---|---|
| Management of type 1 diabetes is a rapidly evolving field, and several international guidelines including the ADA-EASD consensus report on the management of type 1 diabetes in adults (Nov. 2021) and 2022 international consensus meeting on Automated Insulin Delivery (AID) have been released. In this session, the latest updates on the management of type 1 diabetes in terms of diagnosis of type 1 diabetes, the use of CGM/connected insulin pen, AID, and adjuvant therapy will be discussed. | ||
|
S10-1Diagnosis of adult-onset type 1 diabetes | |
|
S10-2Update on continuous glucose monitoring and connected insulin pens in type 1 diabetes | |
|
S10-3Highlights from the international consensus meeting on recommendations for the use of Automated Insulin Delivery (AID) technologies in clinical practice | |
|
S10-4Adjunctive therapies for type 1 diabetes | |
| S14 Clinical diabetes and therapeutics 4 : New era of hormone-based combination for T2D and/or obesity |
13:30~15:30 / Saturday 8 October Convention Hall A, 4F Chairman:Hyun Shik Son, In Joo Kim |
Overview |
|---|---|---|
| Whilst surgical interventions typically result in significant and sustained weight loss, available pharmacotherapies are far less effective, typically decreasing body weight by no more than 5–10%. An emerging class of multi-agonist drugs may eventually bridge this gap. In this session, several gut hormone-based combination treatments for type 2 diabetes, obesity and NAFLD will be introduced. Through this session, we can experience the most updated therapy for type 2 diabetes and its associated metabolic disorders. | ||
|
S14-1Effects of tirzepatide versus insulin glargine on kidney outcomes in participants with type 2 diabetes: a post-hoc analysis from the SURPASS-4 trial | |
|
S14-2The strong on top of the strong: cagrilintide and semaglutide combination for obesity | |
|
S14-3"When they go low, we go high" _ GLP-1/Glucagon dual agonist | |
|
S14-4The novel GIP, GLP-1, and glucagon triple receptor agonist LY3437943: from discovery to clinical proof-of-concept | |
| S16 Clinical diabetes and therapeutics 5 : COVID-19 and diabetes updates |
13:30~15:30 / Saturday 8 October Convention Hall C, 4F Chairman:Jae Myung Yu, Kyungwan Min |
Overview |
|---|---|---|
| The COVID-19 pandemic is still one of the most important global problems in the health care system, and it is expected that it will still take a long time to fully overcome. Diabetes Mellitus (DM) is associated with a poor prognosis for COVID-19, and the COVID-19 pandemic is also known to negatively impact the clinical course of DM. This session was designed to summarize the major clinical evidence on a global scale that has been revealed for COVID-19 and diabetes patients, and to gain new insights into the outcome research that will be continuously studied in the future. | ||
|
S16-1Impact of COVID-19 and associated preventive strategy on cardiometabolic risk | |
|
S16-2New-onset diabetes after COVID-19 infection: it ain’t over till it’s over! | |
|
S16-3Efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19 — results from the DARE-19 global randomized controlled trial | |
|
S16-4Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: from nationwide observational studies in worldwide | |
- Korean Diabetes Association
-
(04146) 101-2104, Lotte Castle President, 109 Mapo-gu, Seoul, Korea
E-mail : icdm@diabetes.or.kr
- Congress Secretariat (Planbear)
-
#1101, 220, Gonghang-daero, Gangseo-gu, Seoul (07806), Republic of Korea
- TEL : +82-2-6734-1011/1012/1013
- E-mail : icdm@diabetes.or.kr
